A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of Cizutamig in Patients With Generalized Myasthenia Gravis (gMG)
Latest Information Update: 21 Nov 2025
At a glance
- Drugs Cizutamig (Primary)
- Indications Myasthenia gravis
- Focus Adverse reactions
- Sponsors Candid Therapeutics
Most Recent Events
- 18 Nov 2025 Status changed from not yet recruiting to recruiting.
- 14 Oct 2025 New trial record